Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06548841
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-30
Brief Title:
Development and Validation of BioSensors for the Identification of Pathogens
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Development and Validation of BioSensors for the Identification of Pathogens
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The recent COVID-19 pandemic has revealed the need to develop tests that are accurate rapid and inexpensive for the diagnosis of infectious diseases This problem is relevant not only for viruses but also for bacteria and parasites the identification of pathogens at low concentrations by simple and accurate methods is still largely unsatisfied because these microorganisms are structurally complex and are incorporated in composite and diverse biological samples which can create relevant interferences in pathogens detection Direct diagnostic approaches such as microscopic examination culture and molecular testing are carried out in equipped laboratories and require long waiting times to obtain the results Recently developed point-of-care POC tests are a group of technologies that miniaturize tests into portable devices such that they can be performed both in well-equipped laboratories and outside the conventional laboratory setting The present study aims to explore the feasibility and adaptability of newly developed platforms to detect 1 a virus SARS-CoV2 2 a bacterium Pseudomonas aeruginosa and 3 a protozoan parasite Leishmania infantum in clinical specimens such as blood and respiratory samples These newly developed platforms are expected to overcome the current limitations of molecular testing high cost time required and need for well-equipped laboratories and rapid testing high number of false-negative results In addition the newly developed platforms may have important clinical application in low-income countries which will benefit from a simple and inexpensive approach to detect the many infectious diseases that affect millions of people each year
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None